|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006754,
umls-concept:C0019693,
umls-concept:C0023413,
umls-concept:C0041044,
umls-concept:C0043474,
umls-concept:C0087111,
umls-concept:C0199176,
umls-concept:C0205179,
umls-concept:C0205225,
umls-concept:C0282116,
umls-concept:C0332173,
umls-concept:C0556987,
umls-concept:C1257890,
umls-concept:C1704410
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1995-3-7
|
|
pubmed:abstractText |
Trimethoprim-sulfamethoxazole (TMP/SMX) is the preferred agent for prophylaxis of Pneumocystis carinii pneumonia (PCP) in patients with HIV infection, but frequent adverse events limit its usefulness. Intermittent dosing and supplementation with leucovorin have been tried in attempts to improve tolerance. We evaluated these strategies in persons with advanced HIV disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0002-9343
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
98
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
177-82
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7847434-AIDS-Related Opportunistic Infections,
pubmed-meshheading:7847434-Adolescent,
pubmed-meshheading:7847434-Adult,
pubmed-meshheading:7847434-Bone Marrow Diseases,
pubmed-meshheading:7847434-Drug Administration Schedule,
pubmed-meshheading:7847434-Drug Therapy, Combination,
pubmed-meshheading:7847434-Female,
pubmed-meshheading:7847434-HIV Infections,
pubmed-meshheading:7847434-Humans,
pubmed-meshheading:7847434-Leucovorin,
pubmed-meshheading:7847434-Male,
pubmed-meshheading:7847434-Pneumonia, Pneumocystis,
pubmed-meshheading:7847434-Proportional Hazards Models,
pubmed-meshheading:7847434-Treatment Outcome,
pubmed-meshheading:7847434-Trimethoprim-Sulfamethoxazole Combination,
pubmed-meshheading:7847434-Zidovudine
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group.
|
|
pubmed:affiliation |
Department of Medicine, University of California San Diego, La Jolla.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
